If you have been told for twenty years that hormone therapy is dangerous, and then read a headline saying the FDA has removed its strongest warning, you are entitled to be confused. Both messages cannot be simply true.
Here is what actually changed, and what it means when you are sitting in a room deciding what to do.
What a boxed warning is
A boxed warning — often called a black box warning — is the most serious warning the FDA applies to a prescription drug label. It appears at the top of the label, inside a border, and it signals risks serious enough that prescribers should weigh them explicitly every time.
Since the early 2000s, estrogen products carried a class-wide boxed warning covering cardiovascular risks, breast cancer, endometrial cancer, and dementia. Class-wide means it applied to all of them: oral tablets, patches, and also the low-dose vaginal creams, inserts, and rings that deliver a fraction of the dose and produce blood levels in the postmenopausal range.
In late 2025 the FDA removed that class-wide boxed warning.
Where the warning came from
The warning traces back to the Women’s Health Initiative, whose first results were published in 2002. WHI was a large randomized trial and a genuine scientific achievement. It was designed to answer whether hormone therapy prevented chronic disease in older women — which is why the average participant was 63 years old, more than a decade past menopause.
The 2002 headline was that combined estrogen-plus-progestin increased breast cancer and cardiovascular risk. Prescriptions collapsed almost overnight. An entire generation of clinicians trained afterward learned to be reflexively wary.
What took much longer to reach the public was the nuance in the later analyses. Risk varied substantially by age and by time since menopause. Women who started therapy within 10 years of menopause, or under age 60, showed a different balance than women who started in their late sixties and seventies. The estrogen-alone arm — women who had had a hysterectomy — did not show the increase in breast cancer that the combined arm did.
Meanwhile the warning sat on every product, including the vaginal ones, where the doses and the systemic exposure are not comparable at all.
What changed, and what did not
The labeling changed. That is the concrete fact. It reflects a reassessment of how the evidence applies by age, by time since menopause, and by product — and a recognition that a single class-wide warning could not honestly represent all of it.
What did not change is anything about your own body. The underlying trial data are the same data. Estrogen still interacts with clotting, with the breast, with the uterine lining. Your history still matters. The removal of a warning from a label is not a finding that hormone therapy is safe for everyone, and anyone marketing it that way is overselling.
What the change does is remove an obstacle to an honest conversation. For years, a woman with severe genitourinary symptoms could be handed a low-dose vaginal cream carrying a warning about dementia and cardiovascular death, read the insert, and never fill it. That warning was not calibrated to what she was being given.
So how do we decide?
The same way we did before the labeling changed, which is the point.
We look at your age and how long it has been since your final period. The balance of benefit and risk is most favorable for women under 60 or within 10 years of menopause. That is where the conversation usually starts.
We go through your personal history: breast cancer, blood clot in a leg or lung, stroke or heart attack, migraine with aura, active liver disease, unexplained vaginal bleeding. Any of these changes the options — sometimes ruling systemic therapy out, sometimes shifting which product makes sense.
We confirm you have had a mammogram in the last 12 months, or we arrange one.
We ask whether you still have a uterus, because if you do, endometrial protection is part of the plan and there is no version where it is skipped.
We choose the product with the risk profile in mind. Transdermal estradiol — a patch, gel, or spray — is our usual starting point because skin delivery avoids first-pass liver metabolism and observational data consistently associate it with lower clot risk than oral estrogen.
And we separate the two questions that are constantly conflated. Systemic therapy for whole-body symptoms is one decision. Low-dose vaginal estrogen for local symptoms is a different decision with a different risk profile. Plenty of women who should not take systemic estrogen can use local therapy.
What this does not mean
It does not mean everyone should be on hormone therapy. It does not mean hormone therapy prevents dementia, extends life, or is an anti-ageing intervention — those claims were not supported before the labeling changed and are not supported now.
It does not mean risk is zero. Venous clot risk, stroke risk that rises with age at initiation, and a small increase in breast cancer risk with combined therapy that grows with duration are all real, and you should be given numbers for your situation rather than adjectives.
And it does not mean the monitoring goes away. Unexpected bleeding on therapy still gets evaluated promptly. Annual review still happens.
The practical upshot
If you were told years ago that hormone therapy was off the table, and nobody has revisited that since, it may be worth revisiting — particularly if you are under 60 or within ten years of your final period, and particularly if your symptoms are affecting your sleep, your work, or your relationships.
And if what you have is dryness, painful sex, or repeat urinary infections, the vaginal estrogen conversation is a separate one, with a much lower bar, and it is worth having regardless of what you decide about systemic therapy.